J4/4)1-3.1(A/4,,42+1*-3.?I*+(1E>-3.)-./01(2-321(.6J7978K.
!
M&',*!#'-N#'*!'(!DCBU!Q!V\°!FmG!4&!CG!u&2(!DCBUX9.
!
9+(2-:2-..
:'*!6.,.42'*!2(5,.66.)02#'*!3/#0(2%&'*!4'!,=2()'*)2(!VYW@WX!#'1#0&-'()!,.!6.,.42'!4'!@#0/(!VY@X!')!,.!#'3)0I
30,2)'!/$60##.12%&'! Vk@vX+!3.#.3)$#2*$'*!)0&)'*! 4'&;!-.#!&('! 2(5,.66.)20(!4'! ,.! -.#02!4=&('! -.#)2'! 4&!)&>'!
421'*)259!w,,'*!'()#.x('()!&(!/.(423.-!50(3)20((',!6.7'&#!')!&(!#')'()2**'6'()!26-0#).()!*&#!,.!%&.,2)$!4'!82'9!
:'&#! 3.&*'! #'*)'! 2(30((&'+! 6&,)25.3)0#2',,'+! ,'&#! $80,&)20(! 8.#2.>,'+! -.#502*! .3306-.1($'! 4'! 306-,23.)20(*!
*$8N#'*+!*.(*!)#.2)'6'()!3&#.)25!.3)&',9!R'*!*<()/N*'*!')!$)&4'*!.--0#)'()!4'*!$,$6'()*!4'!306-#$/'(*20(BDI
Bm9!
!
<+((=-3.)-./4./122=*42>*-...
"#$!0
é
(+0).).*#!)0
è
%!7
é
)
é
0*-
è
#$!
:'*! YW@W! -'&8'()! *'! #$8$,'#! K! )0&)! r1'+! ,'! -,&*! *0&8'()! '()#'! DC! ')! HC! .(*9! l,&*! 5#$%&'()'*! 4.(*! ,'*! -.<*!
4$8',0--$*! ,=2(324'(3'! ')! ,.! -#$8.,'(3'! .&16'()'()! #$1&,2N#'6'()!?! BC! (0&8'.&;! 3.*! '(! "#.(3'OBCC! CCC!
/.>O.(B+!BUE!3/'f!4'*!'(5.()*9!:'*!40(($'*!4&!#'12*)#'!wlWY`RBH!*&#!UFB!-.)2'()*!4&!\0#4!4'!,.!"#.(3'!0()!
60()#$!*&#!U!.(*!&('!-#01#'**20(!4'!,=2(324'(3'!1,0>.,'!4'!F+H!K!_+^OBCC!CCC!/.>2).()*!*02)!&('!.&16'().)20(!
4'!BDCE!')!BFCE!#'*-'3)28'6'()!-0&#!,.!Y@!')!,.!k@v9!@/'f!4'*!621#.()*!,'!#2*%&'!4'!YW@W!#'702()!3',&2!4'!,.!
-0-&,.)20(! 4=.33&'2,+! 4=0y! &(! #L,'! -0**2>,'! 4'! 5.3)'&#*! '(82#0(('6'().&;?! -0,,&)20(+! /<12N('+! .,26'().)20(+!
.()2>20)2%&'*+!.--'(423'3)062'*+!).>.3+!*.(*!%&=.&3&('!$)&4'!('!-'#6'))'!4'!,'!30(52#6'#BD+BG9!!
E,9%.$90%!20.)
è
0$%!3.+-#*%).89$%!
9/1(1E>-3.?!40&,'&#*!.>4062(.,'*!')!42.##/$'!-.#502*!*.(1,.()'*!-#$4062(.()'*+!52**&#'*!0&!52*)&,'*!4'!,.!#$120(!
.(.,'+!-.#502*!.**032$'*!K!4'!,.!52N8#'+!4'*!*21('*!3&).($*+!.#)23&,.2#'*+!/$-.)2%&'*!0&!03&,.2#'*9!R.(*!DCE!4'*!
3.*+!,=2()'(*2)$!4'*!)#0&>,'*!-'&)!26-0*'#!&(!.##P)!4'!,=.,26'().)20(!')!&('!/0*-2).,2*.)20(9!`&!30&#*!4'!,=$80I
,&)20(!-'&8'()!*'(2#!4'*!*)$(0*'*+!.>3N*+!52*)&,'*!0&!033,&*20(*!2()'*)2(.,'*9!:'!#2*%&'!4'!3.(3'#!4&!3L,0(!'*)!
40&>,$!.-#N*!BC!.(*!4=$80,&)20(BD9!
L1+/+G1E>-3.?!,.!3.,-#0)'3)2('!5$3.,'+!/0#*!(06'(3,.)&#'! Vv\X+! '(!-#$*'(3'!4'!*21('*!3,2(2%&'*!')! >20,012%&'*!
$803.)'&#*! 4=2(5,.66.)20(! V.($62'+! @kl+! ,'&303<)0*'+! >2,.(! /$-.)2%&'+! 3#$.)2(2('+! $).)! (&)#2)20((',X+! '*)+! .&!
*'&2,!4'!UCz1O1+!&(!$,$6'()!4255$#'()2',!4=&(!*<(4#06'!50(3)20((',!4&!30,0(!2##2).>,'9!R.(*!&('!6$).I.(.,<*'!
4'!BH!$)&4'*!V^FC!.4&,)'*!')!HFB!'(5.()*X!*'(*2>2,2)$!')!*-$325232)$!$).2'()!#'*-'3)28'6'()!4'!C+_H!VC+mUIC+_FX!')!
C+_^! VC+F_IC+__X+! .8'3! &('! *-$325232)$! 602(4#'! 3/'f! ,='(5.()! ')! ,=.40,'*3'()!?! C+F^!VC+^DIC+m^!n! -dC+CGmX9! :'!
40*.1'!4'!,.!3.,-#0)'3)2('!.!-'#62*!4'!#$4&2#'!4'!^FE!,'!(06>#'!4='(40*30-2'*!.8'3!^E!4'!5.&;!($1.)25*+!3/'f!
,=.4&,)'!')!_E!3/'f!,='(5.()BU9!!!
:=$)&4'! *26&,).($'! 4'*! `T@`! V.3! .()2IT.33/.#06<3'*! 3'#'82*2{+! v\X! ')! -`\@`! V.3! .()2('&)#0-/2,'*!
3<)0-,.*62%&'*!-$#2(&3,$.2#'*X!.24'!K!4255$#'(32'#!k@v!')!Y@B^+BF9!
M()+3?+@1-!?!&('!2,$0I30,0*30-2'!')!&('!A*01.*)#0*30-2'!.8'3!>20-*2'*!-'#6'))'()!4'!3.#.3)$#2*'#!,'*!,$*20(*!?!
42*30()2(&'*!K!-#$4062(.(3'!2,$.,'!')!*)$(0*'*!5#$%&'()'*!4.(*!,.!Y@!n!30()2(&'*!*.(*!.))'2()'!2,$.,'!')!#.#'*!
*)$(0*'*!4.(*!,.!k@v9!!
7,4G-*1-!?!'()$#0I*3.(('#+!'()$#0IWkY+!824$0!3.-*&,'!'(40*30-2%&'!-'&8'()!.24'#!4.(*!4'*!3.*!!4255232,'*B^+BF9!
5,!#
’
&!+!(+%!3$!)0+.)$'$#)!290+).F!3$%!G5@5!
:.!)/$#.-'&)2%&'!.!-0&#!0>7'3)25!&(!30()#L,'!4&#.>,'!4'!,.!-.)/0,012'!')!,'!6.2()2'(!4'!,.!%&.,2)$!4'!82'9!!
N*412-,-(2.)-.?*13-9!!Amino&salycilates!VUI`T`X!'(!BN#'!2()'()20(9!:'*!'55')*!2(4$*2#.>,'*!VBC!K!GUEX!*0()!40*'!
4$-'(4.()*!V(.&*$'*+!$-21.*)#.,12'*+!42.##/$'+!-.(3#$.)2)'*+!T)'8'(*!u0/(*0(XBG9!
.&Corticostéroïdes,&'(!3.*!4=$3/'3!4'*!UI`T`+!.8'3!UCE!4'!#2*%&'*!4='55')*!*<*)$62%&'*!-.#502*!*$8N#'*!4.(*!4'*!
)#.2)'6'()*! 4$-.**.()! BD! *'6.2('*! ?! 0*)$0-0#0*'+! 0*)$0($3#0*'! 4'! ,.! )P)'! 5$60#.,'+! 6<0-.)/2'*+!
3.).#.3)'BD+BG9!!!
N*412-,-(2. )-. A+()9! Immunomodulateurs!'5523.3'*! 4.(*! ,'! 6.2()2'(! 4'*! #$62**20(*! VY@! ')! k@vX9! T&#! mH!
-.)2'()*!.-#N*!H+U!.(*!4'!)#.2)'6'()!-.#!.f.)/20-#2('!V`|`X!')!-0&#*&2)'!-'(4.()!Bm!602*!4'!,=`|`!8*!-,.3'>0+!
,'*!).&;!4'!#'3/&)'*!$).2'()!#'*-'3)28'6'()!4'!DB!')!mE!V-dC+CB_UXBG9!!
.& Biothérapies& anti& TNF.
α
!4.(*! ,'*! 50#6'*! *$8N#'*! ')! #$*2*).()'*! ?! 2(5,2;26.>! 0&! .4.,26&6.>! -0&#! ,.! Y@+!
2(5,2;26.>!*'&,'6'()!4.(*!,.!k@vBD+B^+BF9!W,!(=<!.!-.*!4'!30(*'(*&*!*&#!,.!4&#$'!4&!)#.2)'6'()+!.4.-)$!.&!3.*!-.#!
3.*+!(2!*&#!,'!6.2()2'(!4'!,='5523.32)$!K!,0(1!)'#6'Bm9!
.&L’alimentation!(=2(5,&'!-.*!*&#!,'!30&#*!4'!,.!6.,.42'9!R'*!*&--,$6'().)20(*!V5'#+!.324'!50,2%&'+!f2(3X!802#'!&('!
.,26'().)20(!-.#'()$#.,'!-'&8'()!P)#'!($3'**.2#'*!K!,.!4'6.(4'B^+BF9!
.&Chirurgie9!w(!4'/0#*!4'!30()';)'*!4='(3'+!&('!3/2#'!$,'3)28'!*',0(!,=$)'(4&'!')!,.!428'#*2)$!4'*!,$*20(*!
'*)!#$*'#8$'!.&;!6.,.4'*!#$*2*).()!K!&(!)#.2)'6'()!6$423.,!>2'(!30(4&2)9!
!